Company Overview
AngioDynamics, Inc. operates as a medical technology company dedicated to the design, manufacturing, and sale of medical, surgical, and diagnostic devices primarily utilized for treating peripheral vascular disease, as well as in oncology and surgical settings across the United States and international markets. The firm functions within the broader Healthcare sector, specifically classified under the Medical Instruments & Supplies industry, a classification that defines its operational focus on providing essential equipment for clinical procedures rather than pharmaceutical development. The company's current scale is reflected in a market capitalization of $462.46M, combined with trailing twelve-month revenue of $307.31M and an established workforce of 675 employees. These valuation and revenue figures indicate that AngioDynamics maintains a significant but mid-tier position within its niche, suggesting a substantial asset base and production capacity that supports its global distribution network without yet commanding a dominant market share relative to larger healthcare conglomerates.
Financial Health
The company reported revenue of $307.31M over the trailing twelve months, while simultaneously posting a net income of $-27,710,000 and an EBITDA of $-150,000, revealing a substantial gap between top-line sales and bottom-line profitability that highlights a complex cost structure involving high operating expenses or one-time charges. Despite the net loss, the entity generated positive free cash flow of $300,625, which provides a critical buffer for financial flexibility by allowing the company to fund operations and potential strategic initiatives without immediate reliance on external equity financing. The gross margin stands at 54.6%, indicating a strong pricing power or high-value product mix that covers the direct costs of goods sold, yet the operating margin of -3.1% and profit margin of -9.0% demonstrate that overhead costs and selling, general, and administrative expenses are currently consuming a significant portion of the revenue. In terms of leverage, the company holds $41.64M in cash against $11.79M in debt, resulting in a debt-to-equity ratio of 6.69, which suggests a highly leveraged balance sheet structure where equity capitalization is low relative to liabilities. However, the current ratio of 2.24 indicates robust short-term liquidity, implying that the company possesses more than double the current assets necessary to cover its current liabilities. Finally, the return on equity is recorded at -15.3% and the return on assets at -4.6%, metrics that reveal management has not yet achieved positive capital efficiency, as the company is currently destroying value relative to both the shareholders' equity and the total asset base employed.
Valuation Assessment
The valuation metrics for AngioDynamics show a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is listed at -102.00, a figure that implies the market is pricing in a significant turnaround in expected earnings trajectory rather than current profitability. The price-to-book ratio is 2.65, indicating that the market values the company at a premium of 165% over its tangible book value, which may reflect intangible assets, brand value, or growth potential that is not captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 1.50 and an EV/EBITDA of -2884.07, suggesting that traditional earnings-based multiples are less relevant than sales-based comparisons given the current lack of profitability. Regarding price volatility, the stock has traded between a 52-week high of $13.99 and a 52-week low of $8.36, placing the current market price at a specific point within this historical range that reflects recent market sentiment and trading activity. The beta value of 0.45 indicates that the stock exhibits low price volatility relative to the broader market, moving at roughly half the intensity of the market index, which provides a degree of stability often sought by investors in defensive healthcare sectors despite the company's financial losses.
Growth & Income
AngioDynamics demonstrated a revenue growth rate of 9.0% year-over-year, while earnings growth is listed as N/A due to the company's ongoing net losses, implying that top-line expansion is currently outpacing any potential earnings improvement as the business scales. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which signifies that the firm chooses to reinvest all available cash flow and retained earnings directly into research, development, and manufacturing capacity rather than distributing income to shareholders. This reinvestment strategy is typical for growth-stage medical device companies that prioritize expanding their product portfolio and market penetration over providing immediate income returns to capital providers. Overall, the growth and income profile of AngioDynamics is characterized by positive sales expansion in a growing medical market, coupled with a lack of dividend income and a capital-intensive approach that requires sustained profitability to eventually support shareholder returns.